Head-to-head evidence
Bortezomib vs TQB3602
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Bortezomib
Marketed by Takeda Pharmaceutical Company
NCT00048230 · Phase 3 · completed
Although the record states that participants were randomized, it also describes a single-group, unmasked study and does not document the high-dose dexamethasone comparator in the listed arms. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT06140966 (registry estimate)
TQB3602
Developed by Sino Biopharmaceutical
NCT04275583 · Phase 1 · status unknown
This is a small, open-label, single-arm, non-randomized dose-finding study designed to establish tolerability rather than to test clinical benefit, with no comparator arm and no blinding. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
These results cover the 25-patient dose-escalation phase; the study's dose-expansion phase is not included.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bortezomib's landscape · TQB3602's landscape